Key Decisions in HIV Care: Considerations for Long-Acting Injectable PrEP
Listen as Jason Schafer, PharmD, MPH, shares key considerations for using long-acting injectable cabotegravir for PrEP, including management of missed dosing, stopping PrEP, and screening for HIV while receiving PrEP.
Decera Clinical Education Infectious Disease Podcast · Jason Schafer PharmD MPH
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).
- Listen as he gives his perspectives on:
- The FDA approval of long-acting cabotegravir for PrEP
- Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy
- Considerations for long-acting cabotegravir as PrEP
- Dosing and administration
- Managing missed doses
- Discontinuation
- Delays in HIV diagnoses found in the HPTN 083 study in men
- CDC recommendations for HIV screening while receiving PrEP
Presenter:
Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania
Follow along with the slides at:
https://bit.ly/3wugMOC
See the entire program at:
https://bit.ly/3q2DlGd
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.